📊 NKTX Key Takeaways
Is Nkarta, Inc. (NKTX) a Good Investment?
Nkarta is a pre-revenue biotech company with unsustainable cash burn dynamics. At an annual burn rate of $89.9M against only $39.6M in cash, the company faces critical funding pressure within 5-6 months. While the balance sheet shows no debt and reasonable liquidity, the absence of revenue combined with $122M in annual operating losses indicates the company has not yet achieved commercial viability.
Nkarta remains pre-revenue with persistent operating losses and significant cash burn, offering no clear line-of-sight to profitability. While the balance sheet shows strong liquidity and no debt, reported cash and equivalents appear low relative to the burn rate, elevating funding and dilution risk.
Why Buy Nkarta, Inc. Stock? NKTX Key Strengths
- No long-term debt burden (debt/equity ratio of 0.00)
- Strong liquidity position with 12.69x current ratio relative to liabilities
- Reasonable asset base of $404.2M with positive stockholders equity of $312.3M
- High current ratio indicating strong liquidity
- No long-term debt and modest liabilities
- Large equity base supporting near-term operations
NKTX Stock Risks: Nkarta, Inc. Investment Risks
- Pre-revenue stage with zero commercial product revenue and no clear path to near-term commercialization
- Critical cash runway: $39.6M in cash against $89.9M annual free cash flow burn means less than 6 months of liquidity at current burn rate
- Massive operating losses of $122M annually indicate unsustainable R&D and operational spending relative to resources
- Company will require dilutive equity financing or dramatic operational restructuring to avoid cash depletion
- Minimal insider confidence with only 2 Form 4 filings in 90 days suggests low management activity
- No revenue and sustained net losses
- High operating cash burn raising dilution/financing risk
- Clinical and regulatory execution risk typical of development-stage biotech
Key Metrics to Watch
- Monthly cash burn rate and updated cash runway projections
- Announcement of financing events and dilution impact on shareholders
- Clinical trial progression milestones and FDA approval timelines
- Cash runway (cash + short-term investments vs operating burn)
- Clinical trial milestones and partnership funding
Nkarta, Inc. (NKTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 12.69x current ratio provides a solid financial cushion.
NKTX Profit Margin, ROE & Profitability Analysis
NKTX vs Healthcare Sector: How Nkarta, Inc. Compares
How Nkarta, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Nkarta, Inc. Stock Overvalued? NKTX Valuation Analysis 2026
Based on fundamental analysis, Nkarta, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Nkarta, Inc. Balance Sheet: NKTX Debt, Cash & Liquidity
NKTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Nkarta, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.60 indicates the company is currently unprofitable.
NKTX Revenue Growth, EPS Growth & YoY Performance
NKTX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2020 | $115.0K | -$2.7M | N/A |
| Q2 2020 | $2.3K | -$3.1M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Nkarta, Inc. Dividends, Buybacks & Capital Allocation
NKTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Nkarta, Inc. (CIK: 0001787400)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NKTX
What is the AI rating for NKTX?
Nkarta, Inc. (NKTX) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 70% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NKTX's key strengths?
Claude: No long-term debt burden (debt/equity ratio of 0.00). Strong liquidity position with 12.69x current ratio relative to liabilities. ChatGPT: High current ratio indicating strong liquidity. No long-term debt and modest liabilities.
What are the risks of investing in NKTX?
Claude: Pre-revenue stage with zero commercial product revenue and no clear path to near-term commercialization. Critical cash runway: $39.6M in cash against $89.9M annual free cash flow burn means less than 6 months of liquidity at current burn rate. ChatGPT: No revenue and sustained net losses. High operating cash burn raising dilution/financing risk.
What is NKTX's revenue and growth?
Nkarta, Inc. reported revenue of $0.0.
Does NKTX pay dividends?
Nkarta, Inc. does not currently pay dividends.
Where can I find NKTX SEC filings?
Official SEC filings for Nkarta, Inc. (CIK: 0001787400) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NKTX's EPS?
Nkarta, Inc. has a diluted EPS of $-1.41.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NKTX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Nkarta, Inc. has a SELL rating with 70% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NKTX stock overvalued or undervalued?
Valuation metrics for NKTX: ROE of -33.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NKTX stock in 2026?
Our dual AI analysis gives Nkarta, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NKTX's free cash flow?
Nkarta, Inc.'s operating cash flow is $-88.7M, with capital expenditures of $1.2M.
How does NKTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -33.3% (avg: 15%), current ratio 12.69 (avg: 2).